Sign in

    Robert Driscoll

    Senior Vice President and Senior Equity Research Analyst at Wedbush Securities

    Robert Driscoll is a Senior Vice President and Senior Equity Research Analyst at Wedbush Securities, specializing in biotechnology with a particular focus on oncology and infectious disease. Since joining Wedbush in 2014, Driscoll has covered innovative biotech companies including Arvinas, Kura Oncology, Arcus Biosciences, and IGM Biosciences, leveraging his scientific background to deliver deep, actionable insights. He previously completed a postdoctoral fellowship in molecular biology at Stanford University and began his finance career as a research analyst, following a Ph.D. in Cellular and Molecular Biology from the University of Cambridge and a bachelor's degree from the University of Leeds. Driscoll is recognized for his expertise in biopharmaceuticals, consistently providing high-quality research and recommendations to investors, and holds seniority as a key analyst in his field.

    Robert Driscoll's questions to Compass Therapeutics (CMPX) leadership

    Robert Driscoll's questions to Compass Therapeutics (CMPX) leadership • Q2 2025

    Question

    Robert Driscoll of Wedbush Securities questioned whether the CTX-8371 expansion cohorts would select for PD-L1 expression and asked about the profile of immune-related adverse events (irAEs) observed so far.

    Answer

    CEO Thomas Schuetz stated that the expansion cohorts will not select for PD-L1 expression, maintaining the same criteria as the dose-escalation phase. Regarding safety, he noted no dose-limiting toxicities were seen in the first four cohorts and speculated that the drug's mechanism could potentially lead to a better safety profile, though more data is needed.

    Ask Fintool Equity Research AI

    Robert Driscoll's questions to Compass Therapeutics (CMPX) leadership • Q2 2025

    Question

    Robert Driscoll of Wedbush Securities asked if the CTX-8371 expansion cohorts would select for PD-L1 expression and inquired about any observed immune-related adverse events (irAEs) in the dose-escalation phase.

    Answer

    CEO Thomas Schuetz stated that the company does not plan to change the selection criteria for the CTX-8371 expansion cohorts, meaning they will not select based on PD-L1 status. Regarding safety, he noted no dose-limiting toxicities were seen in the first four cohorts and speculated the drug's mechanism could potentially lead to a better safety profile by anchoring it in the tumor microenvironment.

    Ask Fintool Equity Research AI

    Robert Driscoll's questions to CytomX Therapeutics (CTMX) leadership

    Robert Driscoll's questions to CytomX Therapeutics (CTMX) leadership • Q1 2025

    Question

    Robert Driscoll questioned if EpCAM expression is similarly high in earlier-stage colorectal cancer (CRC), asked about the biology of EpCAM, and inquired about any plans to explore higher doses given the response rate at 10 mg/kg.

    Answer

    CEO Sean McCarthy confirmed that EpCAM has long been established as a CRC antigen expressed throughout the disease's natural history, making it a suitable target for earlier lines. He noted that while EpCAM's biological function isn't fully characterized, its high expression level makes it an ideal 'address' for an ADC. McCarthy also stated that while they have escalated to higher doses, they anticipate finding the maximum assessed dose there and are currently focused on the 7.2, 8.6, and 10 mg/kg expansion cohorts.

    Ask Fintool Equity Research AI